Related Experiment Videos
[Age-related macular degeneration].
Nabil Benyelles1, Gisèle Soubrane
1Centre ophtalmologique universitaire de Créteil, centre hospitalier intercommunal. nabil.benyelles@chicreteil.fr
La Revue Du Praticien
|August 15, 2006
Summary
Age-related macular degeneration (AMD) causes irreversible blindness in adults over 50. While AREDS supplements may help, treatments focus on specific forms like exudative AMD, with ongoing research for new therapies.
Area of Science:
- Ophthalmology
- Retinal Diseases
- Geriatric Medicine
Context:
- Age-related macular degeneration (AMD) is a leading cause of irreversible vision loss in individuals over 50.
- AMD involves the progressive dysfunction of the central retina, retinal pigment epithelium, and choroid.
- The condition is categorized into early/late stages and dry/wet forms.
Purpose:
- To review current understanding and management strategies for age-related macular degeneration (AMD).
- To highlight therapeutic options for different AMD classifications, including dietary supplements and advanced treatments.
- To discuss the ongoing research and clinical trials for novel AMD therapies.
Summary:
- Dietary supplements, like those from AREDS, are recommended for age-related maculopathy.
- Geographic atrophy currently lacks effective treatment.
- Exudative AMD management varies based on choroidal neovascularization characteristics, with laser photocoagulation, PDT, and targeted molecular therapies showing promise.
- Bevacizumab, pegaptanib sodium, and ranibizumab are among molecules investigated for AMD treatment.
- Submacular surgery has not demonstrated significant benefits for neovascular AMD.
Impact:
- Provides a comprehensive overview of AMD diagnosis and treatment options.
- Informs patients and clinicians about current therapeutic standards and emerging research.
- Emphasizes the need for continued research into effective AMD interventions, particularly for geographic atrophy.